The concept is based on blocking immune-checkpoint proteins such as programmed cell death protein 1 (PD-1), programmed death-ligand 1 (PD-L1), or cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), so that the anti-tumour T-cell response remains active [1]. Here, PDCD1 is linked to neoplasm.